Skip to main content
2024 Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Rada Savic, PhD (she/her/hers)

Professor
Univ of California San Francisco

Assessing the impact of malnutrition on pediatric dosing needs through
population PK – lessons from global health and infectious diseases

Rada Savic, PhD
Professor
Department of Bioengineering and Therapeutic Sciences
School of Pharmacy and School of Medicine
University of California San Francisco (UCSF)

Dr. Rada Savic is a Professor at the University of California San Francisco, Program Director of UCSF’s
Clinical Pharmacology and Therapeutics Fellowship, Co-Vice Dean of Graduate Pharmacy Education
Programs, Associate Director of the UCSF Center for TB, and a Chan-Zuckerberg Biohub Investigator. Her
research focuses on data integration and the transformative potential of computational tools and
artificial intelligence to advance drug development and routine drug therapy in infectious diseases
including special populations such as children and pregnant women. Dr. Savic applies innovative,
quantitative and systems pharmacology methods to propose optimized and precision dosing strategies,
data-driven risk stratification algorithms, and inspires new clinical simulation tools across the infectious
disease landscape. Dr. Savic has unique expertise in data, modeling, and knowledge integration that
positions her at the center of many development projects where she collaborates with teams across all
drug discovery and development stages. She is currently a member of the TB Drug Accelerator, a chair of
A5409 (an ACTG funded platform clinical trial for TB regimens), a member of UNITE4TB (EU-based TB
clinical trial collaborative), a member of CDC-funded TB Trial Consortium, and the leader of the data
science and clinical trial technical area in USAID’s funded SMART4TB initiative. She works closely with
BMGF, GMRI, and the TB Alliance on multiple TB drug discovery and development projects.
Dr. Savic has been a critical part of, and key expert in numerous pediatric TB research and clinical trials;
leading projects funded by NIH, WHO, UNITAID, ACTG, USAID, and TBTC. She is a world expert in
pediatric pharmacology, dosing, and clinical trials. Currently, Dr. Savic is a co-chair on S35 – pediatric
dosing of rifapentine for latent TB in young children. She led the data integration and modeling work to
support pediatric FDA and EMEA rifapentine labels for treating latent TB. She serves as a
pharmacometrician and clinical pharmacologist on several pediatric studies to treat all forms of TB. Her
work contributed to WHO pediatric dosing guidelines for linezolid, bedaquline, levofloxacin, and high-
dose rifampin for various forms of TB.

Dr. Savic is a world recognized pharmacologist and expert on drug regimen design and optimal dosing
approaches. She was named the 2021 Leon I. Goldberg Early Investigator Award recipient and a Chan-
Zuckerberg Biohub Investigator in 2022.

Disclosure information not submitted.

Presentation(s):